

EVALUATION OF SERUM IRON AND TRANSFERRIN IN IDIOPATHIC NEPHROTIC SYNDROME PATIENTS ATTENDING AL-HUSSEIN PEDIATRIC NEPHROLOGY CLINIC

By

Ahmed Elsayed Darwish, Mofteh Mohamed Rabeea*, Nayera Mahmoud Al-Akkad*, Gamal Zakariya El-Morsi**

* Pediatric and ** Clinical Pathology Departments, Al-Azhar Faculty of Medicine

ABSTRACT

Background: Nephrotic syndrome is characterized by excessive urinary excretion of albumin and other intermediated-size plasma proteins such as transferrin. Excessive urinary losses of transferrin can produce low serum transferrin level that may lead to low plasma iron concentration and consequently the development of iron resistant microcytic hypochromic anemia.

Aim of the Work: To evaluate changes in serum iron and transferrin and the relationship between the serum and urinary transferrin in the active and remission state of nephrotic syndrome

Patients & Methods: The present work included fifty children with idiopathic nephrotic syndrome (INS), divided into 2 groups: group A (25 cases in activity) and group B (25 cases in remission). These two groups were age and sex matched with a mean age of (7.74 ± 2.45) . All patients in this work were clinically evaluated together with routine laboratory investigations. Levels of serum albumin, urinary alb./creatinine, serum iron, serum ferritin, serum transferrin and urinary transferrin were measured.

Results: This work shows that the level of hemoglobin, MCV, HCT were statistically significantly lower in the cases in active state than cases in remission. The mean serum iron, serum ferritin and serum transferrin were significantly lower in the cases in active state than in the cases in remission. The mean urinary transferrin was statistically significantly higher in the cases in active state than in the cases with remission.

Conclusion: Urinary transferrin can be considered a reliable parameter for early prediction of iron deficiency anemia in children with active nephrotic syndrome.

Key Words: Hemoglobin (HG), Mean corpuscular volume (MCV) Albumin/creatinine ratio (alb./creat) iron deficiency anemia, serum iron, transferrin.

INTRODUCTION

Iron is essential for most living organisms. It is a component of hemoglobin, myoglobin as well as a number of enzymes such as cytochrome oxidase, xanthine oxidase, peroxidase and catalase⁽¹⁾. Iron is derived from dietary ingestion and it is present in red meat, liver, eggs, green leafy vegetables and fortified cereal products⁽²⁾. Transportation of iron is through the mucosal cells of the upper small intestine by the plasma protein transferrin. Transferrin synthesis occurs primarily in the liver and appears to be related to the level of iron storage⁽³⁾. Childhood nephrotic syndrome characterized by heavy proteinuria results in low plasma albumin and edema⁽⁴⁾. The most common age for nephrotic syndrome is between 1.5 and 8 years⁽⁵⁾. It is characterized by marked urinary excretion of albumin and other intermediated-size plasma proteins such as transferrin⁽⁶⁾. Transferrin is important glycoprotein for iron transport between sites of absorption and storage and use in the body. In nephrotic syndrome, excessive urinary losses can produce low serum transferrin level that may lead to decrease serum iron level⁽⁷⁾, patients with nephrotic syndrome commonly

have microcytic hypochromic anemia⁽⁶⁾.

AIM OF THE WORK

To evaluate changes in serum iron and transferrin and the relationship between the serum and urinary transferrin in the active and remission state of nephrotic syndrome.

PATIENT AND METHODS

This study is a cross-sectional included fifty children with idiopathic nephrotic syndrome; from those attending the pediatric nephrology clinic, Al-Hussein University Hospital; and who were under regular follow up. During the period from July 2017 to August 2018. Diagnostic criteria for INS were based on the International Study of Kidney Disease in Children. They were 22 males and 28 females. Their ages ranged from 4 – 14 years.

Inclusion criteria:

Included children with well-established INS with preserved renal function, and under regular followed-up at Al-Hussein pediatric nephrology clinic.

Exclusion criteria:

Patients with renal impairment patients with any manifestations of systemic disease or patients with secondary nephrotic syndrome.

The patients were classified into 2 groups:

Group A: This group included 25 nephrotic patients in activity either 1st time or relapser (recurrence of severe proteinuria > 40 mg/m²/h or urine albumin dipstick $> 2+$ on 3 successive days, often with a recurrence of edema after withdrawal of steroid therapy. It included 11 males and 14 females, their ages ranged from 4.17 -13.17 years with a mean age is (8.12 ± 2.58) years.

Group B: This group included 25 nephrotic patients in remission (marked reduction in proteinuria to < 4 mg/m²/h or urine albumin dipstick of 0 to trace for 3 consecutive days in association with resolution of edema). It included 11 males and 14 females, their ages ranged from 4.83 – 14.08 years with a mean age is (7.36 ± 2.30) years.

Ethical aspects:

The Ethical Committees of Al-Azhar Faculty of Medicine and Pediatric Department approved the study. Informed consent was obtained from parents of all included children. The research protocol did not interfere with any medical recommendations or prescriptions. The aim of the

study and all investigations as well as the risks and benefits of the study have been explained to the parents of the patients. The follow-up of the INS patients guaranteed even in cases of refusal to participate in the study.

All studied patients were subjected to the following:

1. Detailed history taking laying stress on:

Symptoms of nephrotic syndrome, duration of the disease, response to steroid therapy, frequency of relapses, other medications and complications of steroid therapy.

2. Careful clinical examination laying stress on:

- Blood pressure measurement and sign of edema.
- Complications of steroid therapy.
- Systemic examination include all body systems.
- Manifestation of any systemic disease.

3. Laboratory investigations including:

- A. Routine investigations including:
 - CBC, CRP and ESR.
- B. Investigations for nephrotic syndrome:

Serum albumin, urine albumin/creatinine ratio⁽⁸⁾.

C. Serum iron, total iron binding capacity, serum ferritin⁽⁹⁾, serum transferrin and urinary transferrin⁽¹⁰⁾.

Sample Collection

CBC sample was collected under complete aseptic conditions from venous blood that had been anticoagulated with ethylene diamine tetra-acetic acid (EDTA) and thoroughly mixed, which is essential for accurate test results. Test was performed within 6 hours of obtaining the blood specimen because some test results are altered by longer periods of storage, the sample was then analyzed in an automated blood counter instrument. Serum sample was collected from venous blood in plain sterile tubes which were allowed to clot undisturbed for one hour at room temperature. Tubes were centrifuged and the supernatant serum was then pipette into another tube and centrifuged again. The supernatant serum was then transferred to tubes for testing. Urine samples were taken from patients in clean containers, complete urinary albumin/creatinine ratio was done, and another sample for urinary transferrin.

Serum transferrin and urinary transferrin.

Principle of the Method:

In an immunochemical reaction, the proteins contained in the human serum or urine sample form immune complexes with specific antibodies. These complexes scatter a beam of light passed through the sample. The result is evaluated by comparison with a standard of known concentration.

Serum samples are automatically diluted 1:20 with N Diluent and measured. Transferrin in urine is measured from undiluted samples using a separate assay protocol if the readings obtained were outside the measuring range, the assay was repeated using a higher or lower dilution of the sample (not in the urinary transferrin assay protocol⁽¹⁰⁾).

Statistical analysis of the data:

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). Qualitative data were described using number and percent. The Kolmogorov-Smirnov test was used to verify the normality of distribution. Quantitative data were described using range (minimum and maximum), mean,

standard deviation and median. Significance of the obtained results was judged at the 5% level.

The used tests were:

P value was considered significant as the following:

* $P > 0.05$: Non-significant

* $P \leq 0.05$: Significant

Pearson coefficient; to correlate between two normally distributed quantitative variables

Positive = increase in the independent variable leads to increase in the dependent variable.

Negative = increase in the independent variable leads to decrease in the dependent variable.

- ROC curve was used to determine cut off value.

The following statistics can be defined:

Sensitivity: probability that a test result will be positive when the disease is present (true positive rate, expressed as a percentage).

Specificity: probability that a test result will be negative when the disease is not present (true negative rate, expressed as a percentage).

Positive predictive value (PPV): probability that the disease is present when the test is positive (expressed as a percentage).

Negative predictive value (NPV): probability that the disease is not present when the test is negative (expressed as a percentage).

RESULTS**Table (1): Comparison between the two studied groups of cases according to age and sex**

	Cases in active state (n = 25)		Cases in remission state (n = 25)		Test of Sig.	P
	No.	%	No.	%		
Sex					$\chi^2=0.0$	1.000
Male	11	44.0	11	44.0		
Female	14	56.0	14	56.0		
Age (years)					t=1.025	0.311
Range	4.17 – 13.17		4.83 – 14.08			
Mean \pm SD.	2.55 \pm 8.49		2.20 \pm 7.80			
Median	8.25		7.17			

No statistically significant difference between the two groups

Table (2): Comparison between the two studied groups of cases according to age of onset and duration of nephrotic syndrome

	Cases in active state (n = 25)	Cases in remission state (n = 25)	Test of Sig.	P
Age of onset (years)			t=0.041	0.968
Range.	2.25 – 7.0	3.08 – 6.78		
Mean \pm SD.	4.75 \pm 1.35	4.76 \pm 0.83		
4Median	4.67	4.67		
Duration (years)			U= 230.0	0.109
Range	0.25 – 8.58	1.0 – 8.42		
Mean \pm SD.	2.08 \pm 3.73	1.81 \pm 3.02		
Median	3.92	2.67		

No statistically significant difference between the two groups

Table (3): Comparison between the two studied groups of cases according to weight and height

	Cases in active state (n = 25)	Cases in remission state (n = 25)	T	P
Weight (kg)				
Range	20.0 – 55.0	17.0 – 40.0	3.567*	0.001*
Mean ± SD	7.57±30.40	5.23±23.84		
Median	30.0	23.0		
Height (cm)				
Range	107.0 – 150.0	105.0 – 160.0	0.885	0.380
Mean ± SD	11.78±125.6	11.87±122.6		
Median	122.0	120.0		

There is a statistically significant difference between the two groups as regard to the weight but there is

no significant difference in the height.

Table (4): complete blood count in the two studied groups

CBC	Cases in active state (n = 25)	Cases in remission state (n = 25)	t	P
HB (g/dl)				
Range	9.10 – 11.0	11.50 – 13.80	18.439*	<0.001*
Mean ± SD.	0.42±9.72	0.58±12.36		
Median	9.70	12.30		
MCV (fl)				
Range	58.70 – 75.30	72.80 – 85.60	5.237*	<0.001*
Mean ± SD.	4.60±71.38	3.42±77.39		
Median	73.40	77.80		
HCT (%)				
Range	27.40 – 33.0	33.0 – 41.30	15.309*	<0.001*
Mean ± SD.	1.26±29.16	1.98±36.35		
Median	29.10	36.0		
RDW (%)				
Range	18 – 28	11 – 15	16.003*	<0.001*
Mean ± SD.	5.17±21.30	2.79±12.80		
Median	21	13		
TLC(count/mm3)				
Range	6.24 – 11.12	4.41 – 6.50	8.679*	<0.001*
Mean ± SD.	1.58±8.36	0.55±5.45		
Median	8.15	5.50		

PLT(count/mm3)				
Range	350.0 – 460.0	196.0 – 280.0		
Mean ± SD.	24.97±418.9	26.19±244.6	24.083*	<0.001*
Median	419.0	254.0		

There is a significant difference between two groups in all CBC parameters.

Table (5): Comparison between the two studied groups according to serum albumin and Urine albumin / creatinine ratio

	Cases in active state (n = 25)	Cases in remission state (n = 25)	T	P
S. Albumin (g/dl)				
Range	1.70 – 3.0	3.20 – 4.10		
Mean ± SD.	0.39±2.46	0.28±3.65	12.366*	<0.001*
Median	2.50	3.60		
Urine albumin / creatinine ratio				
Range	341.0 – 450.0	10.0 – 27.0		
Mean ± SD.	27.74±386.1	4.81±16.44	65.638*	<0.001*
Median	387.0	18.0		

There is significant difference between the two groups as regard s.

albumin and Urine albumin / creatinine ratio.


Table (6): Comparison between the two studied groups according to specific laboratory data

Specific lab	Cases in active state (n = 25)	Cases in remission state (n = 25)	Test of Sig.	P
Serum iron (µg/ml) Range Mean ± SD. Median	0.11 – 0.33 0.05±0.19 0.20	0.43 – 1.20 0.21±0.73 0.70	t= 12.817*	<0.001*
TIBC(µg/dl) Range Mean ± SD. Median	490.0 – 659.0 42.06±562.6 553.0	240.0 – 402.0 52.81±312.6 300.0	t= 18.511*	<0.001*
Serum Ferritin (ng / ml) Range Mean ± SD. Median	3.0 – 9.0 1.65±4.68 4.0	86.0 – 292.0 49.94±152.7 144.0	U=0.0*	<0.001*
Serum Transferrin (mg/dl) Range Mean ± SD. Median	106.0 – 171.0 12.41±136.3 135.0	209.0 – 312.0 27.04±253.2 253.0	t= 19.649*	<0.001*
Urinary Transferrin (mg/dl) Range Mean ± SD. Median	2.10 – 3.20 0.35±2.62 2.60	0.11 – 0.23 0.03±0.17 0.17	t= 34.588*	<0.001*

There is a marked significant difference between the two groups as regard to Serum iron, TIBC,


Serum Ferritin, Serum Transferrin and Urinary Transferrin.

Figure (1): Correlation between S. albumin (g/dl) and HB in cases in active state




There is positive correlation in active state of nephrotic between S.albumin and hemoglobin syndrome

Figure (2): Correlation between S. albumin (g/dl) and S. transferrin (mg/dl) in cases in active state




There is positive correlation S.transferrin in active state of between S.albumin and nephrotic syndrome.

Figure (3): Correlation between S albumin (g/dl) and U transferrin (mg/dl) in cases in active state




There is a negative Correlation between S. albumin and U. transferrin in cases in active state of nephrotic syndrome.

Figure (4): Correlation between serum iron ($\mu\text{g/ml}$) and HB in cases in active state (+ve correlation)




There is a positive Correlation between S. iron and HB in cases in active state of nephrotic syndrome.

Figure (5): Correlation between serum iron ($\mu\text{g/ml}$) and S transferrin (mg/dl) in cases in active state group (+ve correlation)




There is a positive correlation between S.iron and S. transferrin in cases in active state group of nephrotic syndrome.

Figure (6): Correlation between Serum iron ($\mu\text{g/ml}$) and u transferrin (mg/dl) in cases in active state (-ve correlation)




There is a negative correlation between Serum iron and U. transferrin in cases in active state of nephrotic syndrome.

Figure (7): Correlation between S Transferrin (mg/dl) and HB in cases in active state (+ve correlation)




There is a positive Correlation between S. Transferrin and HB in cases in active state of nephrotic syndrome.

Figure (8): Correlation between U Transferrin (mg/dl) and HB in cases in active state (-ve correlation)




There is a negative correlation between U Transferrin and HB in cases in active state of nephrotic syndrome.

Figure (9): Correlation between serum ferritin (ng / ml) and S Transferrin (mg/dl) in Cases in active state (+ve correlation)




There is a positive correlation between serum ferritin and S. Transferrin in Cases in active state of nephrotic syndrome.

Figure (10): Correlation between serum ferritin (ng / ml) and U Transferrin (mg/dl) in Cases in active state (-ve correlation)



There is a negative correlation between serum ferritin and U. Transferrin in Cases in active state of nephrotic syndrome.

Figure (11): ROC curve for U Transferrin (mg/dl) to predict anemia in cases in active nephrotic syndrome



The best cut off value was 2.8mg/dl with a sensitivity of 90 %, specificity 84%, PPV 88% and NPV 75 % with a diagnostic

accuracy of 89 % (i.e. Idiopathic nephrotic syndrome patients with urinary transferrin < 2.8mg/dl will be anemic).

DISCUSSION

Nephrotic syndrome is characterized by marked urinary excretion of albumin and other intermediated-size plasma proteins such as transferrin⁽¹¹⁾.

Transferrin is very important glycoprotein for iron transport between sites of absorption and storage and use in the body. Iron transport is through the mucosal cells of the upper small intestine by the plasma protein transferrin. Transferrin synthesis occurs primarily in the liver and related to the level of iron storage⁽¹⁾.

Anemia is observed in patients with NS. Anemia is usually microcytic and hypochromic, typical of iron deficiency, but is resistant to therapy with iron because of serum transferrin loss in large amount in the urine of some nephrotic patients⁽¹²⁾.

In an attempt to study some hematologic parameters in children with nephrotic syndrome and to correlate between changes of these parameters and the activity of the disease, we studied 25 nephrotic children in the active state (group I) and another 25

nephrotic children in the remission state (group II). In this study the 2 groups were compared regarding demographic and some clinical data. There were no statistical significant differences regarding sex, age, height, systolic blood pressure and diastolic blood pressure in the 2 studied groups.

In the present study, the mean hemoglobin level, HCT level, and MCV were found to be significantly lower in NS children in active state compared to NS children in remission state ($P < 0.001$). Thus, it can be postulated that some patients had hypochromic microcytic anemia. This conclusion is in accordance with that reported by Aviles et al.⁽¹³⁾, who stated that the hypochromic microcytic anemia in nephrotic patients has different etiologies among which are loss of transferrin in urine which is essential for iron metabolism and lead to iron deficiency anemia not responsive to iron therapy.

Also, malabsorption of iron from the intestine as in chronic renal diseases including nephrotic syndrome might be the cause of iron deficiency anemia. In the current study, serum albumin (1.70 – 3.0 gm/dl) was very highly significantly decreased ($P < 0.001$) in cases in active group as

compared to cases in remission group (3.20 – 4.10 gm/dl). These results agree with the findings of **Babitt et al.**⁽¹⁴⁾. They explained these results by the fact that proteinuria including albuminuria is the initial and single most diagnostic clinic laboratory finding in patients with N.S.

In the current study, serum iron levels (0.11–0.33 $\mu\text{g/ml}$) and ferritin levels (3.0 – 9.0 ng/ml) were highly significantly decreased ($P < 0.01$) in active NS patients as compared to cases in remission group (0.43 – 1.20 $\mu\text{g/ml}$) and (86.0 –292.0 ng/ml) respectively. These data agree with those of Lu et al.⁽¹⁵⁾. They reported that the hypochromic microcytic anemia in nephrotic patients is due to decrease in iron concentration.

In the current study, in cases with activity serum transferrin (106. –171.0mg/dl) was also highly significantly decreased ($P < 0.01$) when compared to those in remission state (209.0 – 312.0 mg/dl). On the other hand urinary transferrin (2.10 – 3.2 mg/dl) was very highly significantly increased ($P < 0.001$) in NS patients in active state as compared to those in remission state (0.11 – 0.23 mg/dl). These results agree with the findings of **Lu et al.**⁽¹⁵⁾, who reported that serum iron and

transferrin levels markedly decreased in NS patients, which may be partially related to the urinary loss of transferrin.

The results of the present study showed a significant negative correlation between serum iron and urinary transferrin in cases with active disease ($r = -0.489$) ($P < 0.013$). On the other hand, in the same cases a significant positive correlation was detected between serum iron and serum transferrin ($r = 0.452$) ($P < 0.023$). These results agree with those of Lu et al.^(15,16). They concluded that in NS patients serum iron, transferrin and erythropoietin levels are markedly decreased in NS patients, which may be partially related to the urinary loss of these elements. Also, they reported that no significant correlation was found regarding clinical and demographic data, which support our study.

Also a significant positive correlation was found between serum iron and HB, ($P < 0.001$) and MCV ($P < 0.009$). These results agree with the findings of **Mitchell et al.**⁽¹⁷⁾ and **Subh et al.**⁽¹⁸⁾, who stated that the hypochromic microcytic anemia in nephrotic patients has different etiologies one of them loss of transferrin in urine which is essential for iron metabolism and lead to iron deficiency anemia.

Our work showed also a significant positive correlation between serum transferrin and HB ($P < 0.001$) and MCV ($P = 0.026$). This was in accordance with that reported by **Mitchell et al.**⁽¹⁷⁾, **Subh et al.**⁽¹⁸⁾ and **Geon et al.**⁽¹⁹⁾, who reported that, transferrin and iron are valuable parameters to make the diagnosis of iron deficiency anemia. These results also agree with **Bartnikas**⁽²⁰⁾, who reported that transferrin is an abundant serum metal-binding protein best known for its role in iron delivery and it has an essential role in erythropoiesis and iron metabolism. Patients deficient in transferrin exhibit anemia.

Our study also demonstrated that in cases in the active state there was a significant negative correlation between urinary transferrin and HB ($P = 0.027$) and MCV ($P < 0.009$). This is in accordance with that reported by **Subh et al.**⁽¹⁸⁾ and **Feinstein et al.**⁽²¹⁾, who stated that the hypochromic microcytic anemia in nephrotic patients has different etiologies among which is loss of transferrin in urine.

The present work demonstrated a significant positive correlation between serum transferrin and serum albumin in nephrotic patients with activity ($r = 0.485$, $P < 0.014$) and a significant negative correlation between urinary

transferrin and serum albumin ($r = -0.407$, $P < 0.044$). These findings agreed with those of **Lu et al.**⁽¹⁵⁾ and **Fletcher**⁽²²⁾, who reported that serum transferrin was found to correlate closely with albumin, and can be recommended as a useful parameter. In the present study, we found that the urinary transferrin is considered highly valid marker in case of anemia in idiopathic nephrotic syndrome.

Urinary transferrin is a reliable to predict anemia in idiopathic nephrotic syndrome patients $P > 0.0001$ and AUC (area under the curve) is 88%. The best cut off value was 2.8 mg/dl with a sensitivity of 90 %, specificity 84% , PPV 88% and NPV 75 % with a diagnostic accuracy of 89% (i.e. Idiopathic nephrotic syndrome patients with urinary transferrin < 2.8 mg/dl will be anemic).

CONCLUSION

The risk of iron deficiency anemia in nephrotic children is more evident during the active stage of the disease as proved by significant changes in the hematological parameters during the activity of the disease. Urinary transferrin is a reliable parameter for prediction of iron deficiency anemia in children with active nephrotic syndrome.

RECOMMENDATIONS

From this study we can recommend the following:

1. Iron profile as well as urinary transferrin should be evaluated in patients with active nephrotic syndrome for early detection of those at risk of iron deficiency anemia.
2. Control of activity of nephrotic syndrome is very important to decrease the risk of developing iron deficiency anemia.
3. Further researches are needed to evaluate the hematological state during different stages of nephrotic syndrome as few studies have been carried out in those children.

REFERENCES

1. **Papanikolaou G, Pantopoulos K (2017):** Systemic iron homeostasis and erythropoiesis. *IUBMB life*, 69(6):399-413.
2. **Erdman J, MacDonald I, Zeisel S (2012):** Present knowledge in nutrition. John Wiley & Sons.
3. **Abbaspour N, Hurrell R, Kelishadi R (2014):** Review on iron and its importance for human health. *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, 19(2), 164.
4. **Macnair T (2008):** Childhood nephrotic syndrome. *BBC Health*; 8(14):56-57.

5. **Morcela D, Kaskel F (2003):** Childhood nephrotic syndrome. Information Resources;138(3):4624-4631.
6. **Keddis M, Bernard M, Karnth H (2007):** Nephrotic syndrome. *Nephrol*; 89(18) 148-153.
7. **Monique, Mysliwiec (2009):** Evaluation of selected parameters of hemostasis in patients with nephrotic syndrome *Przegl. Lek.* 52(2): 77-81.
8. **McPherson, R. A., Pincus, M. R., & Henry, S. (2011):** Clinical diagnosis and management by laboratory methods. Appendix, 5, 1406-14.
9. **Williamson, M. A., & Snyder, L. M. (2014):** Wallach's Interpretation of Diagnostic Tests: Pathways to Arriving at a Clinical Diagnosis. Lippincott Williams & Wilkins.
10. **Johnson A, Rohlf E (1999):** Silverman-LM. Protein. Burtis-CA, and Ashwood-ER.(Eds.): Tietz Textbook of Clinical Chemistry, 477-540.
11. **Kopač M. (2018):** Nephrotic Syndrome in Children—Present State and Future Perspectives. *Journal of Nephrology Research*, 4(1), 139-145.
12. **Park S, Shin J (2011):** Complications of nephrotic syndrome. *Korean journal of pediatrics*, 54(8), 322-328.
13. **Aviles, Iorember, Franca (2017):**"Anemia in nephrotic syndrome: approach to evaluation and treatment." *Pediatric Nephrology* 32(8)1323-1330.
14. **Babitt J, Lin H (2012):** Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, ASN-2011111078.
15. **Lu H, Yuan Y, Zhang W, Liu D, Kuang H (2006):** Concentrations of serum iron and transferrin in children with nephrotic syndrome. *Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics*, 8(6), 467-469.
16. **Lu H, Wang L, Fan Q, Liu D, Zhang W, Yuan Y, Kuang H (2008):** Serum erythropoietin and transferrin in children with idiopathic nephrotic syndrome. *Frontiers of Medicine in China*, 2(3), 286.
17. **Mitchell I, Rubin T, Martin B (2005):** Nephrotic syndrome *Nephrology textbook*, 4th ed. Churchill Livingstone, Edinburgh, London, New York, 110-3.
18. **Subh M, El-Ghannam M, Nazhif ,Hayam K (2006):** Study of hematologic and hemostatic parameters in children with nephrotic syndrome *The Egyptian Journal of Pediatrics*. 20 NL 51-61, Mar.
19. **Geon, Chi Young, Sook Jang (2009):** Soluble transferrin receptor ferritin index and estimated body iron in iron-deficiency anemia in "select" chronic diseases. *Annals of Hematology*; 88(9) 913-915.
20. **Bartnikas T (2012):** Known and potential roles of transferrin in iron biology. *Biometals*, 25(4), 677-686.
21. **Feinstein S, Becker-Cohen R, Algur N, Raveh D, Shalev H, Shvil Y, Frishberg Y (2001):** Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. *American journal of kidney diseases*, 37(4), 736-742.
22. **Fletcher (2001):** A Comparison of Serum Transferrin and Serum albumin as Nutritional Parameters, Westmead, New South Wales, Australia 2145,22-29.

تقييم مستوى الحديد في مصل الدم والترانسفيرين في الأطفال المصابين بالمتلازمة النيفروزية والمترددين على عيادة كلى الأطفال بمستشفى الحسين الجامعي

الملخص العربي

الهدف من البحث: يهدف هذا البحث لمقارنة التغيرات التي تحدث لمستوى الحديد في الدم والترانسفيرين في الدم والبول في الأطفال المصابين بالمتلازمة النيفروزية أثناء نشاط المرض وأثناء كموته.

المرضي و طرق البحث: أجريت هذه الدراسة على خمسين طفلاً يعانون من المتلازمة النيفروزية والمترددين على وحدة كلى الأطفال بمستشفى الحسين الجامعي بالقاهرة لقد تم تقسيمهم الى مجموعتين :

المجموعة الأولى: تضم هذه المجموعة خمسة و عشرين طفلاً (11 من الذكور و 14 من الإناث) أثناء نشاط المرض وتراوحت أعمارهم من 4. إلى 13 سنة.

المجموعة الثانية: تضم هذه المجموعة خمسة و عشرين طفلاً (11 من الذكور و 14 من الإناث) أثناء كموه المرض وتراوحت اعمارهم من 4 إلى 14 سنة.

جميع الحالات أُخضعتُ إلى الآتي (بعد أخذ الموافقة من الأهل):

1. أخذ التاريخ المرضي الكامل.

2. الفحص السريري الشامل لجميع اعضاء الجسم.

3. أبحاث طبية هي:-

أ- صورة دم كاملة ، سرعه الترسيب بروتين سي التفاعلي.

ب- نسبة الألبومين بالدم و نسبة الألبومين / الكرياتينين بالبول.

ج- نسبة الحديد بالدم ، السعة الإجمالية للارتباط بالحديد ،نسبه الفريتين بالدم ،ونسبه الترانسفيرين بالدم والبول.

النتائج:

- أوضحت الدراسة عدم وجود علاقة بين المرضى أثناء كمون المرض أو نشاطه من ناحية مدة المرض أو العمر الذى ظهر به

- اشتملت نتائج التحليل الإحصائي للبيانات على أنّ الأعراض الأكثر شيوعاً عند المرضى أثناء نشاط المرض كانت تورم بالوجه (52%) والقدمين (40%) على العكس من المجموعة الثانية (مرضى أثناء كمون المرض) التى لم يوجد بها هذا العرض.

- لوحظ أيضا انخفاض ملحوظ في نسبة الألبومين بالدم بالمجموعة الاولى أكثر من المجموعة الثانية

- كما لوحظ ارتفاع ملحوظ في نسبة الألبومين / الكرياتينين بالبول بالمجموعه الاولى أكثر من المجموعة الثانية.

- أوضحت الدراسة انخفاض ملحوظ في نسبة الحديد والترانسفيرين في الدم مع ارتفاع في نسبة الترانسفيرين ببول المجموعة الاولى عن المجموعة الثانية.

- أظهرت الدراسة بوضوح الاتي:

- علاقة طردية بين نسبة (الحديد والترانسفيرين في الدم) ونسبه (الهيموجلوبين و الألبومين في الدم) اثناء نشاط المرض

- علاقة عكسية بين نسبة الترانسفيرين في البول ونسبه (الهيموجلوبين والالبومين في الدم) اثناء نشاط المرض

- علاقه طرديه بين نسبة الترانسفيرين في البول ونسبه الالبومين / الكرياتينين في البول في المرضى أثناء الانتكاسة أو اثناء نشاط المرض.

التوصيات:

1- ينبغي تقييم الحديد ودلالاته وكذلك الترانسفيرين البولي في المرضى الذين يعانون من متلازمة الكلوية النشطة للكشف المبكر عن أولئك المعرضين لخطر فقر الدم بسبب نقص الحديد.

2- يجب اعطاء العلاج المناسب للأطفال المصابين بالمتلازمة النيفروزية حتى يتثنى لنا السيطرة على نشاط المرض لتقليل خطر الإصابة بأنيميا نقص الحديد.

3- تكثيف الابحاث لتحديد تغيرات المعاملات الدموية خلال المراحل المختلفة في الاطفال المصابين بالمتلازمة النيفروزية.